Cargando…
Endothelin antagonists: new bullets against lung injury?
Acute lung injury is a syndrome of inflammation and of increased permeability of the blood–gas barrier. Endothelins are thought to exert proinflammatory effects. Kuklin and colleagues show that the endothelin receptor antagonist tezosentan reduces pulmonary edema in endotoxemic sheep, in parallel wi...
Autor principal: | |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2005
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1175897/ https://www.ncbi.nlm.nih.gov/pubmed/15987411 http://dx.doi.org/10.1186/cc3525 |
_version_ | 1782124534218883072 |
---|---|
author | Leeman, Marc |
author_facet | Leeman, Marc |
author_sort | Leeman, Marc |
collection | PubMed |
description | Acute lung injury is a syndrome of inflammation and of increased permeability of the blood–gas barrier. Endothelins are thought to exert proinflammatory effects. Kuklin and colleagues show that the endothelin receptor antagonist tezosentan reduces pulmonary edema in endotoxemic sheep, in parallel with a prevention of protein kinase C-α activation. In turn, the level of some cytokines increased after tezosentan treatment. Whether these contrasting effects of endothelin blockade on inflammatory mechanisms have clinical relevance and whether these agents might benefit patients with acute lung injury is unknown. |
format | Text |
id | pubmed-1175897 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2005 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-11758972005-07-17 Endothelin antagonists: new bullets against lung injury? Leeman, Marc Crit Care Commentary Acute lung injury is a syndrome of inflammation and of increased permeability of the blood–gas barrier. Endothelins are thought to exert proinflammatory effects. Kuklin and colleagues show that the endothelin receptor antagonist tezosentan reduces pulmonary edema in endotoxemic sheep, in parallel with a prevention of protein kinase C-α activation. In turn, the level of some cytokines increased after tezosentan treatment. Whether these contrasting effects of endothelin blockade on inflammatory mechanisms have clinical relevance and whether these agents might benefit patients with acute lung injury is unknown. BioMed Central 2005 2005-04-14 /pmc/articles/PMC1175897/ /pubmed/15987411 http://dx.doi.org/10.1186/cc3525 Text en Copyright © 2005 BioMed Central Ltd |
spellingShingle | Commentary Leeman, Marc Endothelin antagonists: new bullets against lung injury? |
title | Endothelin antagonists: new bullets against lung injury? |
title_full | Endothelin antagonists: new bullets against lung injury? |
title_fullStr | Endothelin antagonists: new bullets against lung injury? |
title_full_unstemmed | Endothelin antagonists: new bullets against lung injury? |
title_short | Endothelin antagonists: new bullets against lung injury? |
title_sort | endothelin antagonists: new bullets against lung injury? |
topic | Commentary |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1175897/ https://www.ncbi.nlm.nih.gov/pubmed/15987411 http://dx.doi.org/10.1186/cc3525 |
work_keys_str_mv | AT leemanmarc endothelinantagonistsnewbulletsagainstlunginjury |